FMP
Lyra Therapeutics, Inc.
LYRA
NASDAQ
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
5.21 USD
0.01 (0.192%)
About
ceo
Dr. Maria Palasis Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://lyratherapeutics.com
exchange
NASDAQ
Description
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its ...
CIK
0001327273
ISIN
US55234L1052
CUSIP
55234L105
Address
480 Arsenal Way
Phone
617 393 4600
Country
US
Employee
88
IPO Date
May 1, 2020
Summary
CIK
0001327273
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
55234L105
ISIN
US55234L1052
Country
US
Price
5.21
Beta
0.23
Volume Avg.
345.67k
Market Cap
311.26M
Shares
-
52-Week
1.96-6.79
DCF
-1.55
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.13
P/B
-
Website
https://lyratherapeutics.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest LYRA News
It looks like there's no news available.
